유잉육종 시장 - 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• In 2023, the US accounted for the maximum share of the Ewing sarcoma Treatment Market in the 7MM, i.e., nearly 53%.
• A molecular-targeted therapy with minimal risk of late toxicities would be beneficial because most Ewing sarcoma Patients are under 20 years old.
• Although there is no standardized second-line treatment for refractory or relapsed Ewing sarcoma, several retrospective studies have reported on conventional salvage treatments.
• Chemotherapy and local therapy (surgery and/or radiation) are dominant in the Ewing sarcoma treatment at the moment.
• The adoption of the VDC/IE regimen has significantly increased survival. Patients with metastatic ES continue to experience negative outcomes, which will increase the demand for future therapeutics.
• The Ewing sarcoma Prognosis has improved over the years due to advances in treatment. The 5-year survival rate for localized Ewing sarcoma is around 70-80%, while the survival rate for metastatic disease is lower, around 30-40%. However, it is important to note that survival rates can vary depending on individual factors and the response to treatment.
• In the updated version 2.2023 of the NCCN guidelines lurbinectedin has been added as a second-line therapy option for Ewing sarcoma (for R/R or metastatic disease).
• Since no therapies are approved for Ewing sarcoma, there is a significant market opportunity for the companies to enter this space and get the first-mover advantage.
• Targeted Ewing Sarcoma Treatments, immunotherapies, precision oncology, and other novel treatments are used to treat some cancer types, but chemotherapy is still the mainstay of treatment for many sarcoma subtypes. There are either none or very few approved drugs for treating many subtypes of sarcoma that can be effectively given to patients, especially after disease progression.
• The usage of off-label therapies may hamper the uptake of new therapies.
• First-line therapy for Metastatic Ewing Sarcoma is similar to that for localized disease and utilizes the same chemotherapy backbone with adequate local control of both primary and metastatic sites.
• The development of Ewing sarcoma Therapies is primarily undertaken by prominent Ewing Sarcoma Companies, including Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, BioAlta, Inhibrx, and others. These key Ewing Sarcoma Companies focus on developing treatments specifically for patients in the second line (2L) and above of treatment
• Due to a potential unexpected significant adverse reaction (SUSAR), Salarius voluntarily stopped enrolling new patients in its Phase I/II trial of seclidemstat as a therapy for Ewing sarcoma last year. The FDA ended its examination of the company's application for seclidemstat in May 2023 and declared that the clinical trial might be restarted.

DelveInsight's "Ewing Sarcoma Treatment Drugs Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology as well as Ewing Sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Ewing Sarcoma Treatment Market Report provides current treatment practices, emerging drugs, Ewing Sarcoma market share of individual therapies, and current and forecasted 7MM Ewing Sarcoma market size from 2020 to 2034. The report also covers current Ewing Sarcoma treatment drugs market practices/algorithms and Ewing Sarcoma unmet medical needs to curate the best opportunities and assess the market's potential.

Ewing Sarcoma Treatment Market

Ewing sarcoma (also known as Ewing's sarcoma) is a cancerous tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing's sarcoma can develop in any bone, it usually affects the long bones, such as the thighbone (femur), shinbone (tibia), and upper arm bone (humerus). The bones of the pelvis are also often affected. Occasionally, the tumor begins in the muscles and soft tissues. The most common symptoms are stiffness, pain, swelling, or tenderness in the bone or the tissue surrounding the bone.

Ewing Sarcoma Diagnosis

The patient's journey begins with symptoms such as persistent bone pain even at rest, swelling, and a large palpable mass on the affected bone. Followed by a visit to the orthopedist, where the patient is suggested diagnostic tests such as MRI, CT scan, and plain radiography. After the diagnosis patient is referred to an oncologist for further treatment. A tissue biopsy is performed of the mass removed from the most aggressive portion of cancer as determined by imaging for confirmatory diagnosis. Once Ewing Sarcoma is confirmed, relevant treatment is given to the patient.

Ewing Sarcoma Treatment

The Ewing sarcoma treatment typically involves a multidisciplinary approach, including surgery, chemotherapy, and radiation therapy. NCCN recommended different chemotherapy combinations to treat localized and metastatic Ewing sarcoma. VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) are recommended by NCCN in the first line and as primary therapy for metastatic disease at initial presentation. For second-line treatment Cyclophosphamide and topotecan, Irinotecan + temozolomide +- NCCN recommends Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin.

Ewing Sarcoma Epidemiology

As the market is derived using a patient-based model, the Ewing Sarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total Ewing Sarcoma Incidence Cases, gender-specific cases of Ewing Sarcoma, age-specific cases of Ewing Sarcoma, and stage-specific cases of Ewing Sarcoma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034. The total incident cases of Ewing sarcoma in the 7MM comprised approximately 1,200 cases in 2023 and are projected to increase during the forecasted period.

• In the 7MM, the highest Ewing Sarcoma Incidence Cases were seen in the United States, accounting of ~41% of the total cases.
• In the EU4, Germany accounted for the highest Ewing sarcoma cases accounting of ~15% of the total cases, , whereas Italy accounted for the lowest.
• In the US, among all the age groups, 10-14 years accounted for the highest number of Ewing sarcoma cases i.e., around 30%, followed by the age-group 15-19 years (26%), in 2023.
• As per the analysis, males are more likely to get Ewing Sarcoma than females. In the US, in 2023, ~300 incident cases of male Ewing Sarcoma were estimated.

Ewing Sarcoma Recent Developments

• On November 12, 2024, Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to elraglusib, a novel glycogen synthase kinase-3 beta (GSK-3B) inhibitor, for the treatment of Ewing sarcoma (EWS).
• On November 12, 2024, the FDA granted rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3B inhibitor, as a potential treatment for patients with Ewing sarcoma.

Ewing Sarcoma Treatment Drugs Market Chapters

The drug chapter segment of the Ewing Sarcoma treatment drugs market report encloses a detailed analysis of the late-stage (Phase II) and Early stage (Phase I/II) Ewing Sarcoma pipeline drug analysis such Seclidemstat (SP-2577), lurbinectedin, Mecbotamab Vedotin (BA3011), and others. There are currently no approved Ewing Sarcoma therapies. It also helps understand the Ewing Sarcoma clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest Ewing Sarcoma news and press releases.

Ewing Sarcoma Emerging Drugs Profile

• Seclidemstat: Salarius Pharmaceuticals

Seclidemstat (SP-2577) inhibits LSD1's enzymatic activity and its scaffolding function. SP-2577 is being studied in an ongoing Phase I/II trial in Ewing sarcoma. Salarius is studying the combination of SP-2577 with topotecan and cyclophosphamide (TC), two agents are commonly given as second or third-line therapy, to improve patient outcomes over TC alone.

• In October 2022, the company voluntarily paused new patient enrollment in its Phase I/II trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas per protocol design. The pause in new patient enrollment was due to a metastatic FET-rearranged sarcoma patient death classified as a suspected unexpected serious adverse reaction (SUSAR).
• Later, in May 2023, the company was notified by FDA that they had completed the review of the company's submission and had concluded that the Ewing Sarcoma clinical trial may be resumed.
• ZEPZELCA (Lurbinectedin): Jazz Pharmaceuticals and PharmaMar

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent.

• In December 2019, PharmaMar and Jazz Pharmaceuticals announced that PharmaMar and Jazz Pharmaceuticals had entered into an exclusive license agreement for lurbinectedin in the United States.
• In the updated version 2.2023 of the NCCN guidelines lurbinectedin has been added as a second-line therapy option for Ewing sarcoma (for R/R or metastatic disease). Under category 2B, this is useful in certain circumstances recommendation.

Ewing Sarcoma Treatment Drugs Market Insights

CDK inhibitors: Proteins involved in RNA transcription, processing, and translation, such as CDK9, CDK12, and CDK13, have shown preclinical promise either alone or in combination with oncoprotein or growth factor targeting, with ongoing trials. Furthermore, CDK4 and CDK6, cell cycle proteins with different functions, have been identified as potential targets unrelated to the fusion oncoprotein in several screens. Trials testing CDK4 and CDK6 inhibitors combined with relapsed Ewing sarcoma Chemotherapy regimens are underway.

The upcoming Ewing Sarcoma Treatment Market Landscape is poised to expand further after new classes, such as tetravalent death receptor 5 (DR5) agonist antibodies, CDK inhibitors, LSD1 inhibitors, AXL inhibitors, and others. Designed to overcome the limitations of earlier-generation agonists and exploit the tumor-specific cell death induced by DR5 activation. DR5 is one of two pro-apoptotic receptors for the trimeric tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Ewing Sarcoma Market Outlook

While advancements in the Ewing Sarcoma treatment, such as chemotherapy and surgical procedures along with radiation therapy, have resulted in better survival rates for some patients, progress has been stagnant for others. The management of high-risk Ewing Sarcoma and other related sarcomas remains controversial, primarily due to an incomplete understanding of their high-risk biological characteristics and relatively low occurrence. These factors have made it challenging to conduct comprehensive clinical trials for the smaller populations of high-risk Ewing Sarcoma patients and the rarer subtypes of sarcomas.

Although there is no standardized second-line treatment for refractory or relapsed Ewing sarcoma, several retrospective studies have reported on conventional salvage treatments. Common salvage regimens involve topotecan, cyclophosphamide, irinotecan, temozolomide, or high-dose chemotherapy (HDC) followed by reinfusion of hematopoietic stem cells. The use of HDC combined with autologous stem cell transplantation (auto-SCT) has been an area of active interest, investigation, and debate for many years. Multiple retrospective and single-arm studies, despite variations in initial conditioning therapy, have shown promising outcomes in patients with high-risk and refractory Ewing Sarcoma. Other potential strategies to target the oncoprotein in Ewing sarcoma include RNA interference, protein degraders, and immunotherapy directed at the novel epitope. Chemotherapy, radiation, surgery, and others are the current Ewing Sarcoma treatment options.

The expected launch of upcoming therapy and greater integration of early patient screening, Ewing Sarcoma medication in secondary care and other clinical settings, research on best methods for implementation, and an upsurge in awareness will eventually facilitate the development of effective treatment options. The significant lack of effective treatment options for Ewing sarcoma underscores the urgent need for advancements in addressing this disease. However, since Ewing Sarcoma is an orphan disease, it is difficult to conduct clinical trials, hence, efforts to increase the number of studies on this orphan disease are urgently needed.

• The Ewing Sarcoma Treatment Market Size in the 7MM is approximately USD 30 million in 2023 and is projected to increase during the forecast period (2024-2034).
• Among EU4 countries, Germany accounts for the maximum Ewing Sarcoma market size i.e. ~25% of the total EU4 and the UK market share.
• Seclidemstat + TC is expected to capture the highest Ewing Sarcoma market share among emerging therapies in the 2L+ setting by 2034.
• The introduction of novel treatment options, including targeted therapies, immunotherapies, and combination regimens, will expand the treatment landscape for Ewing sarcoma to improve survival rates and reduce the side effects associated with traditional treatments like chemotherapy and radiation therapy.

Ewing Sarcoma Drugs Uptake

This section focuses on the uptake rate of potential Ewing Sarcoma drugs expected to be launched in the market during 2020-2034. Salarius Pharmaceuticals is currently working on the development of Seclidemstat as a potential Ewing Sarcoma treatment. This drug is anticipated to be well-received with fast uptake, with a projected probability-adjusted peak share of ~42% in the United States for patients in the second line of treatment and beyond.

Ewing Sarcoma Pipeline Development Activities

The Ewing Sarcoma pipeline segement provides insights into therapeutic candidates in Phase II and Phase I stage. It also analyzes key Ewing Sarcoma Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Ewing Sarcoma pipeline segment covers information on collaborations, acquisitions and mergers, licensing, and patent details for Ewing Sarcoma's emerging therapy.

KOL Views

To keep up with current Ewing Sarcoma Pipeline Drugs Market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on evolving Ewing Sarcoma treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Oncologists; Orthopedists, and Professors; MD, FACS, Chair of the Department of Orthopedic Surgery, and professor at UC Davis Comprehensive Cancer Center in Sacramento, California; MD, Director, Sarcoma Oncology Center, California; and others.

Delveinsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Sarcoma Oncology Center, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Ewing Sarcoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and Ewing Sarcoma Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving Ewing Sarcoma treatment landscape.

The analyst views analyze multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in Ewing Sarcoma trials, progression-free survival is one of the most important primary outcome measures. Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Ewing Sarcoma Therapeutics Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers' concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently. Overall, treatment for bone and joint cancers can easily exceed USD 100,000 for a single patient. This is particularly true if a patient receives surgery, chemotherapy, and radiation therapy. The cost will be much higher if one includes bone-replacing endoprostheses or artificial limbs used in cases requiring amputation.

The Ewing Sarcoma Clinical Trials Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Ewing Sarcoma Therapeutics Market Report Scope

• The Ewing Sarcoma Therapeutics Market Report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the Ewing Sarcoma epidemiology segments and forecasts, disease progression, and Ewing Sarcoma treatment guidelines has been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Ewing Sarcoma Treatment Market Landscape.
• A detailed review of the Ewing Sarcoma Pipeline Drugs Market, historical and forecasted Ewing Sarcoma market size, Ewing Sarcoma market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The patient-based Ewing Sarcoma Market Forecasting report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Ewing Sarcoma Therapeutics Market.

Ewing Sarcoma Therapeutics Market Report Insights

• Patient-based Ewing Sarcoma Market Forecasting
• Therapeutic Approaches
• Ewing Sarcoma Pipeline Drugs Analysis
• Ewing Sarcoma Market Size
• Ewring Sarcoma Market Trends
• Existing and Future Ewing Sarcoma Pipeline Drugs Market Opportunity

Ewing Sarcoma Therapeutics Market Report Key Strengths

• 11 Years Ewing Sarcoma Market Forecast
• The 7MM Coverage
• Ewing Sarcoma Epidemiology Segmentation
• Key Cross Competition
• Ewring Sarcoma Pipeline Drugs Uptake
• Key Ewing Sarcoma Market Forecast Assumptions

Ewing Sarcoma Treatment Market Report Assessment

• Current Ewing Sarcoma Treatment Market Practices
• Ewing Sarcoma Unmet Needs
• Ewing Sarcoma Pipeline Drugs Analysis Profiles
• Ewing Sarcoma Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

Key Questions:

Ewing Sarcoma Treatment Market Insights

• What was the Ewing Sarcoma market size, the market size by therapies, Ewing Sarcoma market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• What will be the impact of Seclidemstat's expected approval by 2025?
• How would CDK inhibitors perform as a class in the second line?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Ewing Sarcoma Epidemiology Insights

• What are the disease risk, burdens, and Ewing Sarcoma unmet needs? What will be the growth opportunities across the 7MM concerning the patient population with Ewing Sarcoma?
• What is the historical and forecasted Ewing Sarcoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which gender has a higher Ewing Sarcoma Incidence?
• How many Ewing Sarcoma patients are diagnosed with localized or metastatic disease?
• Which age group of Ewing Sarcoma has a high patient share?

Current Ewing Sarcoma Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the Ewing Sarcoma treatment? What are the current guidelines for treating Ewing Sarcoma in the US and Europe?
• How many companies are developing therapies for the Ewing Sarcoma treatment?
• How many emerging therapies are in the mid-stage and late stage of development for treating Ewing Sarcoma?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What key designations have been granted for the emerging therapies for Ewing Sarcoma?
• What is the cost burden of current therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, current therapies? Focusing on the reimbursement policies.
• What is the 7MM historical and forecasted Ewing Sarcoma Drugs Market?

Reasons to Buy:

• The Ewing Sarcoma market outlook report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Ewing Sarcoma Pipeline Drugs Market.
• Insights on patient burden/disease Ewing Sarcoma Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Ewing Sarcoma Pipeline Drugs Market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Ewing Sarcoma Pipeline Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing Ewing Sarcoma Clinical Trials Market so that the upcoming Ewing Sarcoma companies can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2 Report Introduction

3 Executive Summary of Ewing Sarcoma

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Ewing Sarcoma Market Overview at a Glance

• 6.1 Market Share (%) Distribution by Therapies in 2023
• 6.2 Market Share (%) Distribution by Therapies in 2034

7 Disease Background and overview

• 7.1 Introduction
• 7.2 Causes
• 7.3 Signs and Symptoms
• 7.4 Staging
  • 7.4.1 The TNM System
• 7.5 Risk Factors
• 7.6 Pathological Diagnosis
• 7.7 Diagnostic Tests
  • 7.7.1 Imaging Tests
  • 7.7.2 Surgical Tests
  • 7.7.3 Other Laboratory Tests

8 Treatment Management of Ewing Sarcoma

• 8.1 Treatment Algorithm

9 Treatment Guidelines for Ewing Sarcoma

• 9.1 NCCN Guidelines: 2023
• 9.2 Ewing Sarcoma: ESMO-PAEDCAN-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and follow-up
• 9.3 Japan Guideline

10 Epidemiology and Patient Population

• 10.1 Key findings
• 10.2 Assumptions and Rationale
• 10.3 Total Incident Cases of Ewing Sarcoma in the 7MM
• 10.4 The United States
  • 10.4.1 Total Incident Cases of Ewing Sarcoma in the United States
  • 10.4.2 Age-specific Cases of Ewing Sarcoma in the United States
  • 10.4.3 Gender-specific Cases of Ewing Sarcoma in the United States
  • 10.4.4 Stage-specific Cases of Ewing Sarcoma in the United States
• 10.5 EU4 and the UK
  • 10.5.1 Total Incident Cases of Ewing Sarcoma in EU4 and the UK
  • 10.5.2 Age-specific Cases of Ewing Sarcoma in EU4 and the UK
  • 10.5.3 Gender-specific Cases of Ewing Sarcoma in EU4 and the UK
  • 10.5.4 Stage-specific Cases of Ewing Sarcoma in EU4 and the UK
• 10.6 Japan
  • 10.6.1 Total Incident Cases of Ewing Sarcoma in Japan
  • 10.6.2 Age-specific Cases of Ewing Sarcoma in Japan
  • 10.6.3 Gender-specific Cases of Ewing Sarcoma in Japan
  • 10.6.4 Stage-specific Cases of Ewing Sarcoma in Japan

11 Patient Journey

12 Key Endpoints in Ewing Sarcoma

13 Emerging Drugs

• 13.1 Key Competitors
• 13.2 Seclidemstat (SP-2577): Salarius Pharmaceuticals
  • 13.2.1 Product Description
  • 13.2.2 Other Development Activities
  • 13.2.3 Clinical Development
    • 13.2.3.1 Clinical Trials Information
  • 13.2.4 Safety and Efficacy
• 13.3 Zepzelca (Lurbinectedin): Jazz Pharmaceuticals and PharmaMar
  • 13.3.1 Product Description
  • 13.3.2 Other Development Activities
  • 13.3.3 Clinical Development
    • 13.3.3.1 Clinical Trials Information
  • 13.3.4 Safety and Efficacy
• 13.4 VERZENIO (abemaciclib): Eli Lilly
  • 13.4.1 Product Description
  • 13.4.2 Clinical Development
    • 13.4.2.1 Clinical Trials Information
• 13.5 IBRANCE (palbociclib): Pfizer
  • 13.5.1 Product Description
  • 13.5.2 Clinical Development
    • 13.5.2.1 Clinical Trials Information
• 13.6 Mecbotamab Vedotin (BA3011): BioAtla
  • 13.6.1 Product Description
  • 13.6.2 Other Development Activities
  • 13.6.3 Clinical Development
    • 13.6.3.1 Clinical Trials Information
• 13.7 Iopofosine I 131 (CLR 131): Cellectar Biosciences
  • 13.7.1 Product Description
  • 13.7.2 Other Development Activities
  • 13.7.3 Clinical Development
    • 13.7.3.1 Clinical Trials Information
• 13.8 TP-1287: Sumitomo Pharma Oncology
  • 13.8.1 Product Description
  • 13.8.2 Other Development Activities
  • 13.8.3 Clinical Development
    • 13.8.3.1. Clinical Trials Information
• 13.9 INBRX-109: Inhibrx
  • 13.9.1 Product Description
  • 13.9.2 Clinical Development
    • 13.9.2.1 Clinical Trials Information

14 Ewing Sarcoma: The 7MM Analysis

• 14.1 Key Findings
• 14.2 Market Outlook
• 14.3 Key Market Forecast Assumptions
• 14.4 Conjoint Analysis
• 14.5 Total Market Size of Ewing Sarcoma in the 7MM
• 14.6 Market Size of Ewing Sarcoma by Therapies in the 7MM
• 14.7 United States Market Size
  • 14.7.1 Total Market Size of Ewing Sarcoma in the United States
  • 14.7.2 Market Size of Ewing Sarcoma by First-line Therapies in the United States
  • 14.7.3 Market Size of Ewing Sarcoma by Second-line and Above Therapies in the United States
• 14.8 EU4 and the UK Market Size
  • 14.8.1 Total Market Size of Ewing Sarcoma in EU4 and the UK
  • 14.8.2 Market Size of Ewing Sarcoma by First-line Therapies in EU4 and the UK
  • 14.8.3 Market Size of Ewing Sarcoma by Second-line and Above Therapies in EU4 and the UK
• 14.9 Japan Market Size
  • 14.9.1 Total Market Size of Ewing Sarcoma in Japan
  • 14.9.2 Market Size of Ewing Sarcoma by First-line Therapies in Japan
  • 14.9.3 Market Size of Ewing Sarcoma by Second-line and Above Therapies in Japan

15 Unmet Needs

16 SWOT Analysis

17 KOL Views

18 Market Access and Reimbursement

• 18.1 The United States
  • 18.1.1 Centre for Medicare & Medicaid Services (CMS)
• 18.2 EU4 and the UK
  • 18.2.1 Germany
  • 18.2.2 France
  • 18.2.3 Italy
  • 18.2.4 Spain
  • 18.2.5 United Kingdom
• 18.3 Japan
  • 18.3.1 MHLW
• 18.4 Economic Burden of Malignant Bone Tumors and Sarcomas

19 Appendix

• 19.1 Bibliography
• 19.2 Report Methodology

20 Delveinsight Capabilities

21 Disclaimer